secwatch.observer — SEC 8-K summary
======================================

Issuer:     MoonLake Immunotherapeutics (MLTX)
CIK:        0001821586
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001213900-24-021233
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MoonLake reports 24-week PsA data with ~60% ACR50; plans Phase 3 HS trials in Q2 2024
--------------------------------------------------------------------------------

- ARGO trial: ~60% ACR50 at week 24; ~40% ACR70; >80% PASI90; ~60% PASI100; low discontinuation ~5%.
- Composite responses: ACR50+PASI100 up to 52%, MDA up to 61%; sonelokimab outperformed adalimumab.
- Regulatory feedback from FDA/EMA supports Phase 3 HS program (VELA) enrolling 800 patients; top-line data expected mid-2025.
- US real-world data: 2M diagnosed HS patients; market opportunity >$10B by 2035; low biologic penetration ~3%.
- Four additional clinical trials imminent in new indications (palmo-plantar pustulosis, juvenile HS, seronegative SpA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821586/000121390024021233/0001213900-24-021233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821586/000121390024021233/ea0201498-8k_moonlake.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-021233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer